US20120165663A1 - Securement for a surgical site marker and deployment device for same - Google Patents
Securement for a surgical site marker and deployment device for same Download PDFInfo
- Publication number
- US20120165663A1 US20120165663A1 US13/416,899 US201213416899A US2012165663A1 US 20120165663 A1 US20120165663 A1 US 20120165663A1 US 201213416899 A US201213416899 A US 201213416899A US 2012165663 A1 US2012165663 A1 US 2012165663A1
- Authority
- US
- United States
- Prior art keywords
- cannula
- marker
- distal end
- securing agent
- actuation member
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/007—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests for contrast media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3417—Details of tips or shafts, e.g. grooves, expandable, bendable; Multiple coaxial sliding cannulas, e.g. for dilating
- A61B17/3421—Cannulas
- A61B17/3439—Cannulas with means for changing the inner diameter of the cannula, e.g. expandable
- A61B2017/3441—Cannulas with means for changing the inner diameter of the cannula, e.g. expandable with distal sealing means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3904—Markers, e.g. radio-opaque or breast lesions markers specially adapted for marking specified tissue
- A61B2090/3908—Soft tissue, e.g. breast tissue
Definitions
- This disclosure relates generally to securing a surgical site marker to prevent migration thereof within a biopsy site and a deployment device to be used in this endeavor.
- the suspicious mass is typically discovered during a preliminary examination involving visual examination, palpation, X-ray, magnetic resonance imaging (MRI), ultrasound imaging or other detection means.
- MRI magnetic resonance imaging
- a sample is taken by biopsy, and then tested to determine whether the mass is malignant or benign.
- This biopsy procedure can be performed by a variety of surgical techniques.
- Treatment often includes a mastectomy, lumpectomy, radiation therapy, or chemotherapy procedure that requires the surgeon or radiologist to direct surgical or radiation treatment to the precise location of the lesion. Because this treatment might extend over days or weeks after the biopsy procedure, and the original features of the tissue may have been removed or altered by the biopsy, it is desirable to insert one or more site markers into the surgical site to serve as a landmark for future identification of the location of the lesion.
- site markers are typically deployed to the biopsy site, the breast is still under compression. However, when the breast is released from compression, the site marker may migrate within the site or even out of the site through a needle tract created by the biopsy device, thereby preventing a surgeon or radiologist from easily locating the precise location of the lesion or biopsied area.
- FIG. 1 is a partial cross-sectional view of a first embodiment of a securing agent deployment device.
- FIG. 2 is a second embodiment of a securing agent and marker deployment device.
- FIG. 3 is a third embodiment of a securing agent deployment device.
- a patient's breast may be placed in compression.
- a target site is biopsied using any one of a variety of biopsy devices.
- a surgeon typically deploys a site marker into the biopsy site (sometimes referred to as a biopsy cavity) formed by the biopsy procedure.
- the marker may be deployed using a marker deployment system, examples of which are described in co-pending U.S. application Ser. Nos. 11,238,295 and 11,305,141, the contents of which are incorporated herein by reference in their entireties.
- an embodiment of this disclosure includes a method of using the body's own haem (blood) as a securing/gluing agent to attach or bond the marker to a specific biopsy site or location, thereby precluding and potentially eliminating migration of the marker away from the desired biopsy site or down a needle track created by the biopsy needle.
- a haemostatic agent is injected into the biopsy site shortly after the marker is deployed into the biopsy site.
- the haemostatic agent causes the blood within the site to clot, thereby locking and securing the marker and tissue into place.
- the marker will remain bonded in place.
- haemostatic agent is sold under the trade name AristaTM, which is manufactured by Medafor, Inc.
- the haemostatic agent is provided in a powder or slurry form to allow for rapid clotting, though other forms of a haemostatic agent may also be used.
- FIG. 1 is a cross-sectional view of a securing agent deployment device 10 that may be used to selectively deploy a securing agent 12 , such as a haemostatic agent, to a biopsy site.
- Deployment device 10 includes an elongated cannula 14 defining an inner lumen 16 therein.
- Cannula 14 is defined by a first end 18 and a second end 20 .
- a normally closed valve 22 may be secured to first end 18 .
- valve 22 is configured as a duckbill valve and is disposed around an exterior of cannula 14 at first end 18 . It is understood however, that other types of normally closed valves may also be employed. It is also understood that the valve 22 may be arranged at first end 18 in other manners than what is shown in FIG. 1 .
- valve 22 may be secured within the interior of cannula 14 .
- actuation portion 24 is connected to second end 20 .
- actuation portion 24 is used to deliver air to inner lumen 16 , to be explained in further detail below.
- securing agent 12 Positioned within inner lumen 16 is a predetermined amount of securing agent 12 .
- securing agent 12 is provided in a powder form, although it is understood that securing agent may be provided in other forms as well.
- securing agent 12 may be provided in a slurry form, a liquid, a gel, or as a pellet or plug.
- a filter element 30 may also be provided to position securing agent 12 within inner lumen 16 .
- first end 18 of deployment device 10 is inserted into a biopsy cavity.
- elongated cannula 14 of deployment device 10 is inserted into a delivery cannula of a biopsy device or, alternatively, an introducer system that is in registration with the biopsy site.
- An exemplary introducer system may be found in commonly owned U.S. Pat. No. 7,347,829, the contents of which are incorporated herein by reference in its entirety.
- Deployment device 10 may include a mounting flange 26 from which one or more latching fingers 28 may extend. Latching fingers 28 may be configured to cooperate with a portion of the biopsy device or a portion of the introducer system to selectively fix deployment device 10 thereto.
- actuation portion 24 which in one exemplary embodiment is configured as a bellows bulb, is activated (in the exemplary illustrated embodiment, depressed) in the direction of arrow A.
- the activation forces fluid, and in one embodiment, air, into cannula 14 at second end 20 and into contact with securing agent 12 .
- normally closed valve 22 is forced open, and at least a portion of securing agent 12 is deployed into the biopsy site.
- securing agent 12 is deployed currently with a site marker (to be explained below).
- securing agent 12 is deployed shortly after site marker is deployed to the biopsy cavity. Once deployed, securing agent 12 accelerates clotting, such that the marker element becomes fixed into position within tissue of the biopsy site and is substantially prevented from migrating within, or out of, the biopsy site.
- deployment device 10 may further include a filter element 30 positioned between first end 18 and second end 20 .
- Securing agent 12 may be positioned between filter element 30 and first end 18 .
- Filter element 30 may be semi-permeable such that securing agent 12 is substantially prevented from passing therethough, but fluid is permitted to pass therethrough.
- filter element 30 is an open cell foam material.
- both marker M and securing agent 12 may be deployed by a single deployment device 50 .
- deployment device 50 will now be described.
- Deployment device 50 includes an outer cannula 52 having an open distal end 54 and defining a lumen 56 therein.
- An inner cannula 58 is positioned within outer cannula 52
- Inner cannula 58 includes a distal end 60 to which a normally closed valve 62 (such as a duckbill valve) is secured.
- An actuation member 64 which is selectively slidable within inner cannula 58 , is further provided.
- a seal member 61 may be provided within inner cannula 58 , through which actuation member 64 passes. Seal member 61 serves to prevent securing material 12 from escaping through a proximal end of inner cannula 58 .
- securing agent 12 is retained within inner cannula 58 and one or more markers M are positioned within lumen 56 of outer cannula 52 .
- Distal end 54 of outer cannula 52 is positioned at the target site.
- Outer cannula 52 may be delivered to the biopsy site through a biopsy delivery cannula or an introducer assembly, as described above.
- marker M may be temporarily retained adjacent distal end 54 by a deformable retaining tab 66 .
- actuation member 64 (which may be a plunger) is activated. Actuation member 64 is moved distally, pushing at least a portion of securing agent 12 through distal end 60 of inner cannula 58 , thereby opening normally closed valve member 62 . Actuation member 64 continues through inner cannula 58 and comes into contact with marker M, thereby pushing both securing agent 12 and marker M past retaining tab 66 and into the biopsy site with a single device and substantially simultaneously.
- securing agent 12 may be provided in plug form that is adhered to at least a portion of marker M. In this configuration, inner cannula 58 may not be needed. Instead, only actuation member 64 is used to eject marker M and attached securing agent 12 plug from outer cannula.
- securing agent 12 is provided as a separate pellet from marker M. In this embodiment, actuation member 64 may push out both marker M and the separate pellet of securing agent 12 to the biopsy site.
- actuation member 64 is a plunger. It may be desirable that actuation member 64 be sized so as to extend a predetermined distance past distal end 54 of outer cannula 52 to insure that marker M and securing agent 12 are fully deployed into the biopsy site.
- FIG. 3 is a partial cross-sectional view of securing agent deployment device 100 that may be used to selectively deploy a securing agent 12 , such as for example, a haemostatic agent, to a biopsy site.
- Deployment device 100 includes an elongated cannula 102 defining an inner lumen 104 therein.
- Cannula 102 includes a first end 106 and a second end (not shown).
- first end 106 Attached to first end 106 is a film or cap member 108 .
- Film or cap member 108 temporarily closes first end 106 , as will be explained below.
- film or cap member 106 is constructed of a bioabsorbable material.
- film or cap member 106 is a heat shrinkable material that is deformed around first end 106 to temporarily close of first end 106 .
- actuation device 110 Disposed within inner lumen 104 is an actuation device 110 having a distal end and proximal end.
- actuation device 110 is a plunger having a piercing tip 112 disposed at the distal end and an actuation member 114 formed at the proximal end.
- a seal member 116 Disposed adjacent to piercing tip 112 is a seal member 116 that is sized to have a size and shape that generally corresponds to inner lumen 104 , but permits actuation device 110 to slide within inner lumen 104 . While actuation device 110 is depicted with a piercing tip 112 at the distal end, it is understood that piercing tip 112 is optional. For example, piercing tip 112 may be eliminated entirely.
- actuation device 110 Prior to operation, actuation device 110 is in a retracted position (shown in FIG. 3 ), whereby the distal end of actuation device 110 and the film or cap member 108 cooperate with inner lumen 104 to form cavity 118 into which securing material 12 is positioned.
- the deployment device 100 is positioned such that a distal end thereof is positioned within the biopsy site. Similar to deployment devices 10 and 50 , deployment device 100 may be positioned in a delivery cannula or an introducer device to deliver distal end 106 to the biopsy site.
- actuation device 110 is moved distally in the direction of arrow A by pressing on actuation member 114 .
- piercing tip 112 may cooperate with seal member 116 to push securing agent 12 towards film or cap member 108 .
- Actuation device 110 may be sized so as to be at least slightly longer than the length of cannula 102 such that when actuation device 110 is fully deployed, piercing tip 112 (or distal end of actuation device 110 ) will rupture or dislodge film or cap 108 from distal end 106 of cannula 102 and expel securing agent 12 into the biopsy site.
- the film or cap 108 is heat shrunk onto distal end 106 , the body heat within the cavity will dislodge film or cap 108 .
- one or more site markers M may also be positioned within cavity 118 such that when actuation device 110 is activated, both securing agent 12 and marker M will be deployed generally simultaneously to the biopsy site.
Abstract
Description
- The present application is a continuation of pending U.S. patent application Ser. No. 12/113,625, filed May 1, 2008, which claims the benefit under 35 U.S.C. §119 to U.S. Provisional Application Ser. No. 60/915,275, filed May 1, 2007. The foregoing applications are each hereby incorporated by reference into the present application in their entirety.
- This disclosure relates generally to securing a surgical site marker to prevent migration thereof within a biopsy site and a deployment device to be used in this endeavor.
- In the diagnosis and treatment of breast cancer, it is often necessary to perform a biopsy to remove tissue samples from a suspicious mass. The suspicious mass is typically discovered during a preliminary examination involving visual examination, palpation, X-ray, magnetic resonance imaging (MRI), ultrasound imaging or other detection means.
- When a suspicious mass is detected, a sample is taken by biopsy, and then tested to determine whether the mass is malignant or benign. This biopsy procedure can be performed by a variety of surgical techniques.
- Regardless of the method or instrument used to perform the biopsy, subsequent examination of the surgical site may be necessary, either in a follow up examination or for treatment of a cancerous lesion. Treatment often includes a mastectomy, lumpectomy, radiation therapy, or chemotherapy procedure that requires the surgeon or radiologist to direct surgical or radiation treatment to the precise location of the lesion. Because this treatment might extend over days or weeks after the biopsy procedure, and the original features of the tissue may have been removed or altered by the biopsy, it is desirable to insert one or more site markers into the surgical site to serve as a landmark for future identification of the location of the lesion.
- However, one problem that arises with site markers is migration. When the site markers are typically deployed to the biopsy site, the breast is still under compression. However, when the breast is released from compression, the site marker may migrate within the site or even out of the site through a needle tract created by the biopsy device, thereby preventing a surgeon or radiologist from easily locating the precise location of the lesion or biopsied area.
- Features and advantages of the disclosure will be apparent from the following detailed description and the appended claims, taken in conjunction with the accompanying drawings, in which:
-
FIG. 1 is a partial cross-sectional view of a first embodiment of a securing agent deployment device. -
FIG. 2 is a second embodiment of a securing agent and marker deployment device. -
FIG. 3 is a third embodiment of a securing agent deployment device. - Referring now to the drawings, exemplary approaches are shown in detail. Although the drawings represent some exemplary approaches, the drawings are not necessarily to scale and certain features may be exaggerated to better illustrate and explain the present disclosure. Further, the approaches set forth herein are not intended to be exhaustive or to otherwise limit or restrict the disclosure to the precise forms and configurations shown in the drawings and disclosed in the following detailed description.
- In a typical biopsy procedure, such as a breast biopsy, a patient's breast may be placed in compression. Next, a target site is biopsied using any one of a variety of biopsy devices. After the biopsy procedure, a surgeon typically deploys a site marker into the biopsy site (sometimes referred to as a biopsy cavity) formed by the biopsy procedure. The marker may be deployed using a marker deployment system, examples of which are described in co-pending U.S. application Ser. Nos. 11,238,295 and 11,305,141, the contents of which are incorporated herein by reference in their entireties.
- To secure the marker in a desired location within the biopsy site, an embodiment of this disclosure includes a method of using the body's own haem (blood) as a securing/gluing agent to attach or bond the marker to a specific biopsy site or location, thereby precluding and potentially eliminating migration of the marker away from the desired biopsy site or down a needle track created by the biopsy needle.
- In connection with one exemplary embodiment of the method, a haemostatic agent is injected into the biopsy site shortly after the marker is deployed into the biopsy site. The haemostatic agent causes the blood within the site to clot, thereby locking and securing the marker and tissue into place. When the breast is released from compression after the biopsy procedure is completed, the marker will remain bonded in place.
- One suitable haemostatic agent is sold under the trade name Arista™, which is manufactured by Medafor, Inc. In one exemplary arrangement, the haemostatic agent is provided in a powder or slurry form to allow for rapid clotting, though other forms of a haemostatic agent may also be used.
-
FIG. 1 is a cross-sectional view of a securingagent deployment device 10 that may be used to selectively deploy asecuring agent 12, such as a haemostatic agent, to a biopsy site.Deployment device 10 includes anelongated cannula 14 defining aninner lumen 16 therein. Cannula 14 is defined by afirst end 18 and asecond end 20. In one arrangement, a normally closedvalve 22 may be secured tofirst end 18. In one exemplary embodiment,valve 22 is configured as a duckbill valve and is disposed around an exterior ofcannula 14 atfirst end 18. It is understood however, that other types of normally closed valves may also be employed. It is also understood that thevalve 22 may be arranged atfirst end 18 in other manners than what is shown inFIG. 1 . For example,valve 22 may be secured within the interior ofcannula 14. - An
actuation portion 24 is connected tosecond end 20. In one arrangement,actuation portion 24 is used to deliver air toinner lumen 16, to be explained in further detail below. Positioned withininner lumen 16 is a predetermined amount ofsecuring agent 12. In one embodiment, securingagent 12 is provided in a powder form, although it is understood that securing agent may be provided in other forms as well. For example, securingagent 12 may be provided in a slurry form, a liquid, a gel, or as a pellet or plug. A filter element 30 (to be explained below in further detail) may also be provided to position securingagent 12 withininner lumen 16. - In operation,
first end 18 ofdeployment device 10 is inserted into a biopsy cavity. In one arrangement,elongated cannula 14 ofdeployment device 10 is inserted into a delivery cannula of a biopsy device or, alternatively, an introducer system that is in registration with the biopsy site. An exemplary introducer system may be found in commonly owned U.S. Pat. No. 7,347,829, the contents of which are incorporated herein by reference in its entirety.Deployment device 10 may include amounting flange 26 from which one or morelatching fingers 28 may extend.Latching fingers 28 may be configured to cooperate with a portion of the biopsy device or a portion of the introducer system to selectivelyfix deployment device 10 thereto. - After
first end 18 is positioned within the biopsy site,actuation portion 24, which in one exemplary embodiment is configured as a bellows bulb, is activated (in the exemplary illustrated embodiment, depressed) in the direction of arrow A. The activation forces fluid, and in one embodiment, air, intocannula 14 atsecond end 20 and into contact with securingagent 12. As the fluid moves throughcannula 14, normally closedvalve 22 is forced open, and at least a portion of securingagent 12 is deployed into the biopsy site. In one embodiment, securingagent 12 is deployed currently with a site marker (to be explained below). In another embodiment, securingagent 12 is deployed shortly after site marker is deployed to the biopsy cavity. Once deployed, securingagent 12 accelerates clotting, such that the marker element becomes fixed into position within tissue of the biopsy site and is substantially prevented from migrating within, or out of, the biopsy site. - In one arrangement, to retain securing
agent 12 withincannula 14 prior to deployment,deployment device 10 may further include afilter element 30 positioned betweenfirst end 18 andsecond end 20. Securingagent 12 may be positioned betweenfilter element 30 andfirst end 18.Filter element 30 may be semi-permeable such that securingagent 12 is substantially prevented from passing therethough, but fluid is permitted to pass therethrough. In one embodiment,filter element 30 is an open cell foam material. - In another exemplary approach, both marker M and securing
agent 12 may be deployed by asingle deployment device 50. Referring toFIG. 2 ,deployment device 50 will now be described. -
Deployment device 50 includes anouter cannula 52 having an opendistal end 54 and defining alumen 56 therein. Aninner cannula 58 is positioned withinouter cannula 52Inner cannula 58 includes adistal end 60 to which a normally closed valve 62 (such as a duckbill valve) is secured. Anactuation member 64, which is selectively slidable withininner cannula 58, is further provided. In one embodiment, aseal member 61 may be provided withininner cannula 58, through whichactuation member 64 passes.Seal member 61 serves to prevent securingmaterial 12 from escaping through a proximal end ofinner cannula 58. - In operation, securing
agent 12 is retained withininner cannula 58 and one or more markers M are positioned withinlumen 56 ofouter cannula 52.Distal end 54 ofouter cannula 52 is positioned at the target site.Outer cannula 52 may be delivered to the biopsy site through a biopsy delivery cannula or an introducer assembly, as described above. In one embodiment, marker M may be temporarily retained adjacentdistal end 54 by adeformable retaining tab 66. - To deploy securing
agent 12 and marker M, actuation member 64 (which may be a plunger) is activated.Actuation member 64 is moved distally, pushing at least a portion of securingagent 12 throughdistal end 60 ofinner cannula 58, thereby opening normally closedvalve member 62.Actuation member 64 continues throughinner cannula 58 and comes into contact with marker M, thereby pushing both securingagent 12 and marker M past retainingtab 66 and into the biopsy site with a single device and substantially simultaneously. - In another embodiment, securing
agent 12 may be provided in plug form that is adhered to at least a portion of marker M. In this configuration,inner cannula 58 may not be needed. Instead, onlyactuation member 64 is used to eject marker M and attached securingagent 12 plug from outer cannula. In yet another embodiment, securingagent 12 is provided as a separate pellet from marker M. In this embodiment,actuation member 64 may push out both marker M and the separate pellet of securingagent 12 to the biopsy site. - In one arrangement,
actuation member 64 is a plunger. It may be desirable thatactuation member 64 be sized so as to extend a predetermined distance pastdistal end 54 ofouter cannula 52 to insure that marker M and securingagent 12 are fully deployed into the biopsy site. - Another embodiment of a securing
agent deployment device 100 is shown inFIG. 3 .FIG. 3 is a partial cross-sectional view of securingagent deployment device 100 that may be used to selectively deploy a securingagent 12, such as for example, a haemostatic agent, to a biopsy site.Deployment device 100 includes anelongated cannula 102 defining aninner lumen 104 therein.Cannula 102 includes afirst end 106 and a second end (not shown). - Attached to
first end 106 is a film orcap member 108. Film orcap member 108 temporarily closesfirst end 106, as will be explained below. In one embodiment film orcap member 106 is constructed of a bioabsorbable material. In another embodiment, film orcap member 106 is a heat shrinkable material that is deformed aroundfirst end 106 to temporarily close offirst end 106. - Disposed within
inner lumen 104 is anactuation device 110 having a distal end and proximal end. In one embodiment,actuation device 110 is a plunger having a piercingtip 112 disposed at the distal end and anactuation member 114 formed at the proximal end. Disposed adjacent to piercingtip 112 is aseal member 116 that is sized to have a size and shape that generally corresponds toinner lumen 104, but permitsactuation device 110 to slide withininner lumen 104. Whileactuation device 110 is depicted with a piercingtip 112 at the distal end, it is understood that piercingtip 112 is optional. For example, piercingtip 112 may be eliminated entirely. - Prior to operation,
actuation device 110 is in a retracted position (shown inFIG. 3 ), whereby the distal end ofactuation device 110 and the film orcap member 108 cooperate withinner lumen 104 to formcavity 118 into which securingmaterial 12 is positioned. Next, thedeployment device 100 is positioned such that a distal end thereof is positioned within the biopsy site. Similar todeployment devices deployment device 100 may be positioned in a delivery cannula or an introducer device to deliverdistal end 106 to the biopsy site. - To deploy securing
agent 12,actuation device 110 is moved distally in the direction of arrow A by pressing onactuation member 114. In the embodiment shown inFIG. 3 , piercingtip 112 may cooperate withseal member 116 to push securingagent 12 towards film orcap member 108.Actuation device 110 may be sized so as to be at least slightly longer than the length ofcannula 102 such that whenactuation device 110 is fully deployed, piercing tip 112 (or distal end of actuation device 110) will rupture or dislodge film or cap 108 fromdistal end 106 ofcannula 102 and expel securingagent 12 into the biopsy site. In another embodiment wherein the film orcap 108 is heat shrunk ontodistal end 106, the body heat within the cavity will dislodge film orcap 108. - In another embodiment, one or more site markers M (
FIG. 3 , shown in phantom) may also be positioned withincavity 118 such that whenactuation device 110 is activated, both securingagent 12 and marker M will be deployed generally simultaneously to the biopsy site. - While the present disclosure has been particularly shown and described with reference to the foregoing embodiments, it should be understood by those skilled in the art that various alternatives to the embodiments of the disclosure described herein may be employed in practicing the disclosure without departing from the spirit and scope of the disclosure as defined in the following claims. It is intended that the following claims define the scope of the invention and embodiments within the scope of these claims and their equivalents be covered thereby. This description of the disclosure should be understood to include all novel and non-obvious combinations of elements described herein, and claims may be presented in this or a later application to any novel and non-obvious combination of these elements. The foregoing embodiments are illustrative, and no single feature or element is essential to all possible combinations that may be claimed in this or a later application.
Claims (20)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/416,899 US20120165663A1 (en) | 2007-05-01 | 2012-03-09 | Securement for a surgical site marker and deployment device for same |
US14/044,611 US9622822B2 (en) | 2007-05-01 | 2013-10-02 | Securement for a surgical site marker and deployment device for same |
US15/472,561 US10159540B2 (en) | 2007-05-01 | 2017-03-29 | Securement for a surgical site marker and deployment device for same |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91527507P | 2007-05-01 | 2007-05-01 | |
US12/113,625 US8137320B2 (en) | 2007-05-01 | 2008-05-01 | Securement for a surgical site marker and deployment device for same |
US13/416,899 US20120165663A1 (en) | 2007-05-01 | 2012-03-09 | Securement for a surgical site marker and deployment device for same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/113,625 Continuation US8137320B2 (en) | 2007-05-01 | 2008-05-01 | Securement for a surgical site marker and deployment device for same |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/044,611 Continuation US9622822B2 (en) | 2007-05-01 | 2013-10-02 | Securement for a surgical site marker and deployment device for same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120165663A1 true US20120165663A1 (en) | 2012-06-28 |
Family
ID=40073079
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/113,625 Active 2028-12-05 US8137320B2 (en) | 2007-05-01 | 2008-05-01 | Securement for a surgical site marker and deployment device for same |
US13/416,899 Abandoned US20120165663A1 (en) | 2007-05-01 | 2012-03-09 | Securement for a surgical site marker and deployment device for same |
US14/044,611 Active 2030-05-31 US9622822B2 (en) | 2007-05-01 | 2013-10-02 | Securement for a surgical site marker and deployment device for same |
US15/472,561 Active 2028-10-08 US10159540B2 (en) | 2007-05-01 | 2017-03-29 | Securement for a surgical site marker and deployment device for same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/113,625 Active 2028-12-05 US8137320B2 (en) | 2007-05-01 | 2008-05-01 | Securement for a surgical site marker and deployment device for same |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/044,611 Active 2030-05-31 US9622822B2 (en) | 2007-05-01 | 2013-10-02 | Securement for a surgical site marker and deployment device for same |
US15/472,561 Active 2028-10-08 US10159540B2 (en) | 2007-05-01 | 2017-03-29 | Securement for a surgical site marker and deployment device for same |
Country Status (1)
Country | Link |
---|---|
US (4) | US8137320B2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8137320B2 (en) | 2007-05-01 | 2012-03-20 | Suros Surgical Systems, Inc. | Securement for a surgical site marker and deployment device for same |
US9427186B2 (en) | 2009-12-04 | 2016-08-30 | Endomagnetics Ltd. | Magnetic probe apparatus |
US10634741B2 (en) | 2009-12-04 | 2020-04-28 | Endomagnetics Ltd. | Magnetic probe apparatus |
US9968340B2 (en) * | 2012-10-24 | 2018-05-15 | William Zinnanti | Biopsy device with automatic aspiration |
BR112015022129B1 (en) | 2013-03-11 | 2022-04-19 | Endomagnetics Ltd | Hyposmotic solutions for lymph node detection |
US9234877B2 (en) | 2013-03-13 | 2016-01-12 | Endomagnetics Ltd. | Magnetic detector |
US9239314B2 (en) | 2013-03-13 | 2016-01-19 | Endomagnetics Ltd. | Magnetic detector |
CN113558782A (en) | 2015-06-04 | 2021-10-29 | 安都磁学有限公司 | Marker materials and forms for Magnetic Marker Localization (MML) |
KR20220110526A (en) * | 2019-12-03 | 2022-08-08 | 보스톤 싸이엔티픽 싸이메드 인코포레이티드 | agonist delivery device |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030233101A1 (en) * | 2002-06-17 | 2003-12-18 | Senorx, Inc. | Plugged tip delivery tube for marker placement |
US20050059957A1 (en) * | 2003-01-17 | 2005-03-17 | Campbell Carey V. | Catheter assembly |
US20080039819A1 (en) * | 2006-08-04 | 2008-02-14 | Senorx, Inc. | Marker formed of starch or other suitable polysaccharide |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10512470A (en) * | 1995-01-18 | 1998-12-02 | メドケム プロダクツ,インコーポレーテッド | Apparatus and method for applying a hemostatic agent to tissue |
AU4763296A (en) * | 1995-02-03 | 1996-08-21 | Inbae Yoon | Cannula with distal end valve |
US6347241B2 (en) | 1999-02-02 | 2002-02-12 | Senorx, Inc. | Ultrasonic and x-ray detectable biopsy site marker and apparatus for applying it |
US6161034A (en) | 1999-02-02 | 2000-12-12 | Senorx, Inc. | Methods and chemical preparations for time-limited marking of biopsy sites |
US8282573B2 (en) | 2003-02-24 | 2012-10-09 | Senorx, Inc. | Biopsy device with selectable tissue receiving aperture orientation and site illumination |
US8361082B2 (en) | 1999-02-02 | 2013-01-29 | Senorx, Inc. | Marker delivery device with releasable plug |
US7189206B2 (en) | 2003-02-24 | 2007-03-13 | Senorx, Inc. | Biopsy device with inner cutter |
US6725083B1 (en) | 1999-02-02 | 2004-04-20 | Senorx, Inc. | Tissue site markers for in VIVO imaging |
US6862470B2 (en) | 1999-02-02 | 2005-03-01 | Senorx, Inc. | Cavity-filling biopsy site markers |
US20090216118A1 (en) | 2007-07-26 | 2009-08-27 | Senorx, Inc. | Polysaccharide markers |
US7983734B2 (en) | 2003-05-23 | 2011-07-19 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
US6123683A (en) * | 1999-06-22 | 2000-09-26 | Tri-State Hospital Supply Corporation | Pill delivery apparatus |
US6605047B2 (en) * | 2001-09-10 | 2003-08-12 | Vivant Medical, Inc. | Biopsy marker delivery system |
US7347829B2 (en) | 2002-10-07 | 2008-03-25 | Suros Surgical Systems, Inc. | Introduction system for minimally invasive surgical instruments |
US8062230B1 (en) | 2004-10-14 | 2011-11-22 | Suros Surgical Systems, Inc. | Surgical site marker delivery system |
US7761137B2 (en) | 2005-12-16 | 2010-07-20 | Suros Surgical Systems, Inc. | Biopsy site marker deployment device |
US20090171198A1 (en) * | 2006-08-04 | 2009-07-02 | Jones Michael L | Powdered marker |
US8137320B2 (en) | 2007-05-01 | 2012-03-20 | Suros Surgical Systems, Inc. | Securement for a surgical site marker and deployment device for same |
-
2008
- 2008-05-01 US US12/113,625 patent/US8137320B2/en active Active
-
2012
- 2012-03-09 US US13/416,899 patent/US20120165663A1/en not_active Abandoned
-
2013
- 2013-10-02 US US14/044,611 patent/US9622822B2/en active Active
-
2017
- 2017-03-29 US US15/472,561 patent/US10159540B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030233101A1 (en) * | 2002-06-17 | 2003-12-18 | Senorx, Inc. | Plugged tip delivery tube for marker placement |
US20050059957A1 (en) * | 2003-01-17 | 2005-03-17 | Campbell Carey V. | Catheter assembly |
US20080039819A1 (en) * | 2006-08-04 | 2008-02-14 | Senorx, Inc. | Marker formed of starch or other suitable polysaccharide |
Also Published As
Publication number | Publication date |
---|---|
US20170196653A1 (en) | 2017-07-13 |
US20080294092A1 (en) | 2008-11-27 |
US20140031683A1 (en) | 2014-01-30 |
US8137320B2 (en) | 2012-03-20 |
US10159540B2 (en) | 2018-12-25 |
US9622822B2 (en) | 2017-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10159540B2 (en) | Securement for a surgical site marker and deployment device for same | |
EP2550927B1 (en) | Fibrous marker and intracorporeal delivery thereof | |
US20080058640A1 (en) | Marker formed of starch or other suitable polysaccharide | |
US20080228164A1 (en) | Implant delivery system | |
US20050119562A1 (en) | Fibrous marker formed of synthetic polymer strands | |
US20090216118A1 (en) | Polysaccharide markers | |
JP2011518639A (en) | Assembly with hemostatic and radiation detectable pellets | |
EP4279015A2 (en) | Apparatus for direct marking | |
US8298211B2 (en) | Push button pull back device | |
AU2005302639A1 (en) | Fibrous marker formed of synthetic polymer strands | |
US20100160777A1 (en) | Reverse deployment device | |
US20210282888A1 (en) | Apparatus for delivering biopsy cavity marker |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SUROS SURGICAL SYSTEMS, INC., INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MARK, JOSEPH L.;NICOSON, ZACHARY R.;SIGNING DATES FROM 20080507 TO 20080509;REEL/FRAME:028482/0452 |
|
AS | Assignment |
Owner name: GOLDMAN SACHS BANK USA, NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNORS:HOLOGIC, INC.;BIOLUCENT, LLC;CYTYC CORPORATION;AND OTHERS;REEL/FRAME:028810/0745 Effective date: 20120801 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP, MASSACHUSETTS Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239 Effective date: 20150529 Owner name: HOLOGIC, INC., MASSACHUSETTS Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239 Effective date: 20150529 Owner name: CYTYC CORPORATION, MASSACHUSETTS Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239 Effective date: 20150529 Owner name: SUROS SURGICAL SYSTEMS, INC., MASSACHUSETTS Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239 Effective date: 20150529 Owner name: BIOLUCENT, LLC, MASSACHUSETTS Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239 Effective date: 20150529 Owner name: GEN-PROBE INCORPORATED, MASSACHUSETTS Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239 Effective date: 20150529 Owner name: THIRD WAVE TECHNOLOGIES, INC., MASSACHUSETTS Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239 Effective date: 20150529 Owner name: CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP, MASS Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239 Effective date: 20150529 |
|
AS | Assignment |
Owner name: CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP, MASSACHUSETTS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529 Effective date: 20150529 Owner name: GOLDMAN SACHS BANK USA, NEW YORK Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT;ASSIGNORS:HOLOGIC, INC.;BIOLUCENT, LLC;CYTYC CORPORATION;AND OTHERS;REEL/FRAME:044432/0565 Effective date: 20120801 Owner name: THIRD WAVE TECHNOLOGIES, INC., MASSACHUSETTS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529 Effective date: 20150529 Owner name: HOLOGIC, INC., MASSACHUSETTS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529 Effective date: 20150529 Owner name: CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP, MASS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529 Effective date: 20150529 Owner name: SUROS SURGICAL SYSTEMS, INC., MASSACHUSETTS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529 Effective date: 20150529 Owner name: BIOLUCENT, LLC, MASSACHUSETTS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529 Effective date: 20150529 Owner name: GEN-PROBE INCORPORATED, MASSACHUSETTS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529 Effective date: 20150529 Owner name: CYTYC CORPORATION, MASSACHUSETTS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529 Effective date: 20150529 |